Medigen Biotechnology Corp. reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported sales was TWD 484.71 million compared to TWD 185.65 million a year ago. Net loss was TWD 81.71 million compared to TWD 64.1 million a year ago. Basic loss per share from continuing operations was TWD 0.59 compared to TWD 0.46 a year ago. Basic loss per share was TWD 0.59 compared to TWD 0.46 a year ago.